CalciMedica shares surge 22.33% intraday amid anticipation of key March 2026 clinical development milestones.

CalciMedica surged 22.33% intraday trading following news of critical clinical development milestones in mid-March 2026. The biopharma firm faces key updates on its pipeline, including recruitment status and data releases, which investors use to reassess its value. The market appears to price optimism around regulatory progress and operational discipline in the sector. While Oppenheimer cut its price target from $20 to $10, maintaining an "Outperform" rating, this bearish adjustment contradicted the intraday rally, suggesting the clinical news drove the move rather than analyst revisions.